Compare Ally Financial Inc (ALLY) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Enveric Biosciences Inc — how do they compare? Ally Financial Inc trades at $45.22 (market cap $13.97B), while Enveric Biosciences Inc trades at $1.37 (market cap $5.44M). The key difference: Ally Financial Inc is far larger — about 2568× Enveric Biosciences Inc's market cap, and Ally Financial Inc pays a 2.63% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ALLY | ENVB | |
|---|---|---|
Market Cap | $13.97B | $5.44M |
Sector | Financials | Health |
52-Week High | $47.25 | $17.40 |
52-Week Low | $35.96 | $1.28 |
Dividend Yield | 2.63% | — |
Enterprise Value | — | $529.67K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $45.59, up 1.06% today, with a bearish technical signal but strong analyst support. The stock shows attractive valuation with a P/E of 11.07 and P/B of 1.05, supported by consistent earnings beats in recent quarters. Recent news highlights value potential and a strategic focus on auto lending and digital banking, with a dividend payment scheduled for May 2026.
The outlook is positive given the consensus price target of $55.25, implying significant upside. Risks include declining operating cash flow and macroeconomic pressures on net interest margins. The stock presents a value opportunity with disciplined capital return, but investors should monitor credit quality and interest rate sensitivity.
ENVB trades at $1.35, down 5.59% today, with a bearish technical signal from moving averages. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
Outlook remains speculative with high financial risk due to negative ROE and ROA, but analyst consensus is 75% buy. Key risks include clinical trial outcomes and cash burn, while institutional interest is supported by a recent $13.9M private placement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
